市場調查報告書
商品編碼
1271782
透皮給藥系統市場——按類型、按應用、按最終用途和預測,2023 年至 2032 年Transdermal Drug Delivery Systems Market - By Type By Application By End-use & Forecast, 2023 - 2032 |
由於對非侵入式藥物輸送系統的需求不斷增長,全球透皮藥物輸送系統市場預計從 2023 年到 2032 年將呈現適度的複合年增長率。
口服、局部和經皮等非侵入性給藥方法無痛且副作用比侵入性程序少。 這些特性使這些系統多年來廣受歡迎,推動了高度依賴自我管理的患者的採用,並由於降低了給藥頻率而提高了患者的依從性。
透皮給藥系統市場按類型、應用、最終用途和地區劃分。
按類型分,半固體型透皮貼劑的市場規模有望擴大至2032年。 噴霧劑等半固體透皮給藥產品具有給藥直接、副作用少等特點。 它還可以預先測量的劑量給藥,以提高患者的療效。 此外,軟膏、凝膠和噴霧劑等各種半固體透皮製劑的可用性也將有利於到 2032 年採用。
在應用方面,心血管疾病領域在 2022 年已累積超過 19% 的市場份額。 由於全球心血管疾病 (CVD) 的高患病率,預計未來幾年產品滲透率將增加。 據世界衛生組織稱,心血管疾病是導致死亡的主要原因,每年在全世界造成約 1790 萬人死亡。 此外,在治療這些疾病時,越來越多的人接受無創給藥裝置,這將進一步加強透皮給藥系統市場的增長前景。
到 2032 年,家庭保健領域的透皮給藥系統的最終用途可能會達到公允價值。 透皮給藥系統的最新創新促進了它們在家庭護理應用中的採用。 這些藥物輸送適合家庭使用,因為它們減少了與腸胃外給藥相關的風險和不適。 從長遠來看,對微創治療的需求不斷增長,預計也將有助於增加對該產品的需求。
預計到 2032 年,亞太地區的透皮給藥系統市場將顯著擴大。 不斷增長的老年人口和對慢性病的易感性增加正在增加該地區對透皮給藥系統的需求。 據世界衛生組織預測,到2040年,中國將有28%的人口超過60歲。 亞太地區是 Hisamitsu Pharmaceutical Co., Ltd. 等主要行業參與者的所在地,該公司不斷致力於產品創新。 這也將對未來幾年的整體市場動態產生積極影響。
Global Transdermal Drug Delivery System Market is expected to exhibit a decent CAGR from 2023 to 2032, owing to the rising demand for non-invasive drug delivery systems. Oral, topical, transdermal, and other non-invasive drug delivery methods are painless and demonstrate fewer side effects than invasive procedures. These attributes have added to the popularity of these systems over the years and boosted their adoption among patients with higher dependency on self-administration and improved patient compliance due to reduced dosing frequencies.
The overall transdermal drug delivery system market is categorized on the basis of type, application, end-use, and region.
Regarding the type, the transdermal drug delivery system market size from the semisolids segment is anticipated to garner commendable gains through 2032. Semisolid transdermal drug delivery products such as sprays enable direct drug delivery and have lesser side effects. Additionally, they help administer pre-measured doses in patients for better treatment. Moreover, the high availability of a wide range of semi-solid transdermal drug delivery products such as ointment, gels, sprays, and others will favor their adoption through 2032.
With respect to application, the cardiovascular diseases segment accumulated over 19% market share in 2022. High prevalence rate of cardiovascular disorders (CVDs) globally will increase product uptake in the forthcoming years. As per WHO, CVDs are a prominent cause of death, resulting in around 17.9 million mortalities across the globe annually. Moreover, the increased acceptance of non-invasive drug delivery devices for the treatment of these diseases will further create a strong growth outlook for the transdermal drug delivery system market.
Based on end-use, the transdermal drug delivery system industry from home care settings segment could record a decent valuation by 2032. Recent innovations in transdermal drug delivery systems have fostered their adoption in home care applications. These drug delivery systems reduce the risks and discomfort associated with the parenteral route of administration, making them suitable for home usage. This apart, the increasing demand for minimally invasive treatment will further contribute to strong product demand in the long run.
Asia Pacific transdermal drug delivery system market is poised to expand substantially through 2032. Rising geriatric population and its higher susceptibility to chronic disorders have increased the demand for transdermal drug delivery systems in the region. According to WHO, 28% of the total population in China will be above 60 years by 2040. Asia Pacific is also home to key industry players such as Hisamitsu Pharmaceutical Co., Inc. and others constantly indulged in product innovations. This will also have a positive impact on the overall market dynamics in the coming years.